The lawsuits are alleging Gilead has infringed Idenix's recently-granted, co-owned European patent EP 1523489, which covers 2'-methyl-2'-fluoro nucleosides for treating the hepatitis C virus (HCV).
written on 17.03.2014
The lawsuits are alleging Gilead has infringed Idenix's recently-granted, co-owned European patent EP 1523489, which covers 2'-methyl-2'-fluoro nucleosides for treating the hepatitis C virus (HCV).
See our Cookie Privacy Policy Here